Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost
A week after finally getting its bone-building drug across the finish line, Amgen on Monday unveiled the annual price tag carried by the injected osteoporosis treatment Evenity: $21,900.
One in two postmenopausal women in the United States have weakened bones that make them highly susceptible to fracturing. Evenity functions predominantly as a bone anabolic agent that stimulates bone growth by inhibiting a protein called sclerostin, which ceases the production of bone and enhances its breakdown.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.